Gene Therapy for the Treatment of Neurological Disorders : Central Nervous System Neoplasms

Abstract

Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults with a median survival of 16.2–21.2 months post diagnosis (Stupp et al., N Engl J Med 352(10): 987–996, 2005). Because of its location, complete surgical resection is impossible; additionally because GBM is also resistant to chemotherapeutic and radiotherapy approaches, development of novel therapies is urgently needed. In this chapter we describe the development of preclinical animal models and a conditionally cytotoxic and immune-stimulatory gene therapy strategy that successfully causes tumor regression in several rodent GBM models.